Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
- PMID: 34758431
- PMCID: PMC8890776
- DOI: 10.1016/j.drugpo.2021.103518
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
Abstract
Background: Research into the therapeutic and naturalistic uses of psychedelics for improving outcomes related to mental health disorders has generated increasing interest in recent years. While controlled clinical trials of psychedelics have signaled benefits for treating substance use disorders, this area has not been well studied in the context of naturalistic psychedelic use. This study sought to investigate the possible relationship between recent naturalistic psychedelic use and subsequent daily illicit opioid use among people who use drugs (PWUD).
Methods: Data (2006-2018) were drawn from three harmonized prospective cohorts of community-recruited PWUD in Vancouver, Canada. We used multivariable generalized linear mixed-effects modeling (GLMM) to estimate the independent association between psychedelic use and subsequent daily illicit opioid use.
Results: Among 3813 PWUD at baseline, 1093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past six months. Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95% Confidence Interval: 0.29 to 0.70).
Conclusion: While confirmation in other settings is required, these findings align with growing evidence that psychedelic use may be associated with detectable reductions in subsequent substance use including illicit opioid use.
Keywords: Mental health; Opioid use; Psychedelics; Substance use disorders.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declarations of Interest Drs. Argento, Mackay and Christie are consultants to Numinus Wellness, a Canadian mental health company interested in the use of psychedelics for medical purposes. Numinus Wellness was not involved in the collection of data, the writing of this manuscript, or the decision to submit findings for publication. M-J Milloy is the Canopy Growth professor of cannabis science at the University of British Columbia, a position created by unstructured gifts to the university from Canopy Growth, a licensed producer of cannabis, and the Government of British Columbia's Ministry of Mental Health and Addictions. The University of British Columbia has also received unstructured funding from NG Biomed Ltd to support him.
References
-
- Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166. 10.1177/0269881119897615. - DOI - PubMed
-
- Ahmad F, Rossen L, & Sutton P (2020). Vital statistics rapid release: Provisional drug overdose death counts. Retrieved from https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
-
- Argento E, Capler R, Thomas G, Lucas P, & Tupper KW (2019). Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug and Alcohol Review, 38(7), 781–789. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
